Literature DB >> 8583604

Penile electromyography and its smooth muscle content: interpretation of 25 impotent patients.

A A Sattar1, L A Merckx, E Wespes.   

Abstract

PURPOSE: We studied the correlation of penile electromyography and the cavernous smooth muscle content in 25 impotent patients.
MATERIALS AND METHODS: After a complete hormonal and diagnostic evaluation, all patients underwent corpus cavernosum penile electromyography and a penile biopsy of the corpus cavernosum with the biopsy gun device. Cavernous tissue was analyzed using immunohistochemical stain actin anti-actin and computerized image analysis.
RESULTS: Of the patients 20 had normal and 5 had abnormal corpus cavernosum penile electromyography. Of the 20 patients with normal corpus cavernosum penile electromyography 12 (60%) showed a normal percentage of cavernous smooth muscle and 8 (40%) had abnormal muscle content. All patients with abnormal corpus cavernosum penile electromyography showed abnormally low cavernous smooth muscle fibers.
CONCLUSIONS: Our study showed an overall low sensitivity between corpus cavernosum penile electromyography potential amplitude and cavernous smooth muscle content. However, a high specificity (100%) of corpus cavernosum penile electromyography in the diagnosis of abnormal low cavernous muscle content was observed. Further studies with a larger number of patients are needed to evaluate corpus cavernosum penile electromyography as a predictor of cavernous smooth muscle function.

Entities:  

Mesh:

Year:  1996        PMID: 8583604

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  Activation of the iNOS/NO/cGMP pathway by Revactin® in human corporal smooth muscle cells.

Authors:  Monica G Ferrini; Andrea Abraham; Leslie Graciano; Sabine Nguyen; Jesse N Mills; Jacob Rajfer
Journal:  Transl Androl Urol       Date:  2021-07

2.  Relaxation degree: a new concept in erectile dysfunction.

Authors:  O Kayigil; A Metin
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.